All News

Lead investigators, presenters, and the chair of this year’s European Society of Cardiology Congress, John McMurray, MD, discussed the meeting highlights and recapped important data.

Discussions of social determinants of health might focus on the obvious ones—like income or education—while overlooking some other social determinants that impact health in complex ways.

At the 2024 European Society of Cardiology Congress (ESC), key research in cardiology care included studies conducted on cardiovascular disease risk among women, cardiac distress and smoking, and lipoprotein(a).

This interview accompanies the first podcast in our National Recovery Month series with Michael Lynch, MD, attending emergency physician and medical toxicologist at the University of Pittsburgh Medical Center.

Compared with those without vitiligo, patients with vitiligo have higher health care access and utilization but report a lower quality of life.

Patients who had weight-loss surgery were more likely to have managed their high blood pressure compared with those who used medications and modes of management.

The trend of food insecurity continued in 2023, according to a report from the Department of Agriculture.

A review by authors from China examines evidence involving different treatment approaches.

Sophia Humphreys, PharmD, director of formulary management at Sutter Health, discusses how group purchasing organizations (GPOs) influence integrated delivery networks (IDNs) and hospitals in making formulary decisions, including the adoption of biosimilars.

Using artificial intelligence (AI) in breast cancer screenings in the United Kingdom could be cost-effective and improve health outcomes after identifying more cancers.

The tentative approval cannot take effect because a competing product was granted market exclusivity.

Recombinant Hirudin (rH) inhibited the polarization of M2-type macrophages and protease-activated receptor-1 (PAR-1) in diffuse large B-cell lymphoma (DLBCL).

The FINEARTS-HF late-breaking data were forefront at the 2024 European Society of Cardiology Congress in London.

Alzheimer disease research is yielding breakthroughs with blood tests and brain scans that can enhance early diagnosis, while new drugs promise to slow the disease and improve patients’ lives.

Early data suggest chimeric antigen receptor (CAR) T-cell therapy can achieve meaningful long-term results.

The European Respiratory Society (ERS) Congress 2024 will delve into the balance between human expertise and the growing role of artificial intelligence (AI) in respiratory medicine.

According to some reports, the draft rule imposes strict limitations on telehealth prescriptions even as advocates push for extension of current flexibilities.

Neil Goldfarb, president and chief executive officer of the Greater Philadelphia Business Coalition on Health (GPBCH), previews the variety of themes and sessions at the upcoming GPBCH Annual Wellness Summit taking place September 10, 2024.

The rates of discontinuation due to inefficacy or adverse events for biosimilars and originators of etanercept and adalimumab were similar, according to an analysis of a prospective registry.

Educational principles implemented after 1998 may have led to lower mortality rates in patients with colorectal cancer (CRC) receiving care from doctors trained after that point.

The eye condition, which can induce the loss of central vision, could see effective treatment options pending FDA approval.

The final report unveils actionable steps for integrating equity into health technology assessment.

A case report highlights a rare instance of parkinsonism following CAR T-cell therapy for multiple myeloma.

The first real-world study highlights benefits for adults aged 60 years and older who receive the respiratory syncytial virus (RSV) vaccine.

New findings add to the relationship between red meat and processed meat consumption and the risk of type 2 diabetes.

A recent study has found that higher serum levels of B-cell activating factor and anti-CCP3 are associated with a reduced risk of developing chronic lymphocytic leukemia (CLL), suggesting potential biomarkers for assessing CLL risk.

The HERCULES study of tolebrutinib is the first and only to show reduced confirmed disability progression at 6 months in nonrelapsing secondary progressive multiple sclerosis (MS).

An analysis on the state of pharmaceutical drug pricing revealed that, despite rebates, consumers' out-of-pocket costs have grown faster than their insurers' prices.